Video

View from the Thoraxcenter: ACC 22 Late-breaking Science Preview

Published: 25 Mar 2022

  • Views:

    Views Icon 954
  • Likes:

    Heart Icon 5

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022

Trials covered in detail include:

00:39: PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial (NCT03067844)

03:20: VALOR-HCM: Mavacamten as an Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients with Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy (NCT04349072)

05:04: Results of the EDIT-CMD Randomized Clinical Trial: Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in Angina and Nonobstructive Coronary Arteries (NCT04777045)

06:57: PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs with Heart Failure (NCT04514458)

08:58: The FAME 3 Trial: Quality of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery (NCT02100722)

11:21: The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis (NCT03317002)

13:25: Results From the PARTITA Trial: Catheter Ablation of Ventricular Tachycardia After the First Implantable Cardioverter Shock (NCT01547208)

15:29: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses (NCT01586910)

17:15: A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism after Transcatheter Aortic-valve Replacement (NCT03284827)

19:47: 3-year Efficacy Outcomes from the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation on Blood Pressure Reduction in Patients on Antihypertension Medications (NCT02439775)